-
CHMP highlights: March 2023
CHMP highlights: March 2023
-
CHMP highlights: March 2023
CHMP highlights: March 2023
EMA's human medicines committee (CHMP) recommended 9 new medicines for approval in the EU at its March 2023 meeting
-
Bimervax recommended for approval in the EU
Bimervax recommended for approval in the EU
-
Bimervax recommended for approval in the EU
Bimervax recommended for approval in the EU
EMA recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) for use as a booster in people aged 16 years and above
-
First anniversary of DARWIN EU®
First anniversary of DARWIN EU®
-
First anniversary of DARWIN EU®
First anniversary of DARWIN EU®
DARWIN EU® has completed its first studies, generating real-world evidence to support regulatory decision making. A call to onboard ten additional data partners in 2023 is now open
-
Achievements of the Regulatory Science Strategy
Achievements of the Regulatory Science Strategy
-
Achievements of the Regulatory Science Strategy
Achievements of the Regulatory Science Strategy
EMA published a report summarising the mid-term achievements of the Regulatory Science Strategy to 2025
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal